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Abstract
Although mortality rates have been declining, prostate cancer
accounts for a large percentage of cancer diagnoses worldwide.
Sipuleucel-T (Provenge®), an autologous cellular immunotherapy
targeted against the antigen expressed in most prostate cancers,
has been shown to increase the median survival rate of castrationresistant prostate cancer. Even so, the therapeutic risks and
benefits, as well as financial implications, all currently play a role in
the governmental decision to reimburse for this new therapy.
According to the National Comprehensive Cancer Network {NCCN),
prostate cancer accounted for 25 percent of cancer diagnoses in men
during 2009. 1 While this incidence is high, the mortality rates from
prostate cancer have been declining due to earlier detection and treatment through increased public awareness. However, earlier treatment
of non-life-threatening prostate cancer also may lead to the occurrence
of seemingly unnecessary side effects and even impaired quality of life.
The risks and benefits associated with treating prostate cancer at this
minimally symptomatic stage, especially its financial implications, all play
a role in the decision of insurance companies to reimburse the therapeutic use of a new drug. This is the case for sipuleucel-T (Provenge®), a
novel treatment for castration-resistant prostate cancer that is currently
being evaluated by Medicare for reimbursement eligibility.
Several factors are taken into consideration when treating a patient with
prostate cancer, including their estimated life expectancy, comorbidities,
therapy side effects, and patient preference. 1 The selected treatment
is also based on the patient's assigned risk group. The assigned risk
group is a designated placement that considers the patient's Gleason
grade, prostate specific antigen {PSA) level, and pathologic staging of
the cancer, all of which determine the cancer's overall severity. Historically, treatment has included active surveillance of the tumor, radiation,
surgery, androgen deprivation therapy, and/or chemotherapy.
Sipuleucel-T is an autologous cellular immunotherapy targeted against
the antigen expressed in most prostate cancers, prostatic acid phosphatase (PAP). 2 The therapeutic vaccine contains mononuclear cells,
including antigen presenting cells (APCs), which are obtained from the
patient's blood. These cells are cultured with PA2024, a fusion protein
made up of PAP fused to granulocyte-macrophage colony-stimulating
factor (GM-CSF). 3 Although the mechanism of action is not entirely
clear, it is thought that once administered to the patient, the APCs
present the antigen to T lymphocytes which elicit an immune response
against the antigen.
About three days before infusion, the patient has blood drawn, and the
autologous APCs are obtained via leukapheresis. 2 These cells are sent
to the manufacturing facility, cultured with the fusion protein, and then
sent back to the clinic where the prepared infusion can be administered
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to the patient. Sipuleucel-T is given at two-week intervals for three
doses. 3 Approximately 30 minutes before each infusion, the patient must
be pre-medicated with acetaminophen and an antihistamine as prophylactic treatment for infusion-related events. Common adverse reactions
as~ociated with sipuleucel-T include acute infusion reactions, chills,
fatigue, fever, back pain, nausea, joint ache, and headache.4
The immunotherapy provided by sipuleucel-T introduces a novel type of
drug therapy that can increase the median survival rate of castration-resistant prostate cancer by an average of four months {from 21.7 months
to 25.8 months).5 This is according to the lmmunotherapy for Prostate
Adenocarcinoma Treatment (IMPACT) trial, the double-blind, placebocontrolled, multicenter phase 3 study that persuaded the Food and
Drug Administration (FDA) to approve the drug. This study also found
that sipuleucel-T reduced the risk of death by 22 percent relative to the
placebo group (hazard ratio, 0.78; 95% confidence interval [Cl], 0.61
to 0.98; P=0.03) and increased the 36-month survival probability from
23.0 percent in the placebo group to 31.7 percent in the sipuleucel-T
group. However, questions have been raised in regards to the IMPACT
trial through an editorial published by The New England Journal of
Medicine. 6 This editorial specifically addresses the GM-CSF received
through sipuleucel-T's administration and its potential benefit in fighting
the cancer.7 It proposes that the increase in median survival rate established by this trial may not only be associated with the drug, but with the
overall stimulation of the immune system provided by GM-CSF. If this
is the case, the editorial states that the placebo group should also have
received GM-CSF to produce more of an effect on the median survival
rate of patients treated with sipuleucel-T.
In comparison to the other available treatments, NCCN guidelines
for prostate cancer only recommend sipuleucel-T for asymptomatic
or minimally symptomatic patients with a life expectancy greater than
s~x months and with no visceral disease. 1 This is due to the inability to
directly measure the drug's effect since the normal markers of improvement for prostate cancer, including a decline in PSA or improvement of
bone or CT scans of metastasized tumors, are not observed. Currently,
docetaxel with prednisone or mitoxantrone with prednisone are the firstline treatments recommended for this type of prostate cancer and have
been shown to demonstrate a survival rate of 18.9 months and 16.5
months, respectively. 4
The economic implications of many cancer treatment options have
come under increased scrutiny in recent years. Since chemotherapeutic
agents often represent some of the most expensive FDA-approved
medications currently available, critics argue that their overall benefit to
patients should be closely studied before these medications gain final
approval. 8 Medications used to treat cancers that have reached the
metastatic stage, such as sipuleucel-T, are even more controversial due
to their mostly marginal increases in patient quality of life or life expectancy with a given disease. In order to accurately measure the value of
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a pharmacologic therapy, cost-utility analyses (CUAs) are commonly
used.8·9 CUAs are a special type of cost-effectiveness study that use
quality-adjusted life years (QALYs) to evaluate the overall benefits of a
drug. According to the National Institute for Health and Clinical Excellence (NICE}, using QALYs provides a means of estimating the number
of quality months or years that an individual can expect to live if they
undergo a given treatment. 10 In these studies, life quality is calculated
using an aggregation of different variables, including a patient's pain
level, overall mobility and disposition. This type of analysis is well-suited
for studying chemotherapy agents, such as sipuleucel-T, because
QALYs represent a measure of success for many types of metastatic or
incurable cancers. The current NICE threshold for cost-effective therapy
is £20,000-£30,000 ($32,548-$48,882} per QALY and is considered a
benchmark for new medications to meet in order for final FDA approval.
Currently, the required three doses of sipuleucel-T cost approximately
$93,000. 11 •12 Given the 4.1-month median increase in life expectancy
for patients in its pivotal clinical trial, sipuleucel-T's cost per month of
extended life is around $23,000. 12 These cost estimates, however, only
included the amount the pharmaceutical company charges to formulate each individual patient's doses. Additional costs, such as those
associated with the leukapheresis procedures required to harvest an
individual's cells and administrative expenses, probably make the total
cost to patients much higher than the initial estimate. In addition to these
costs, critics argue, many patients using sipuleucel-T still require traditional chemotherapy, increasing the overall treatment costs even more.
While there are currently no guidelines in place governing the QALY cost
threshold in the United States, a widely accepted limit of $50,000 per
QALY is one means to evaluate sipuleucel-T. 13 In spite of the expense,
many large private insurance companies, including Humana, Aetna,
Kaiser Permanente, Cigna, and AmeriHealth, have already chosen to
cover the cost of three treatments in patients with asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer. 6•14•15
While coverage by private insurers has largely been uncontested, the
Centers for Medicare and Medicaid Services (CMS) announced in June
201 Othat they would perform a national coverage analysis (NCA} at the
request of local Medicare contractors. The purpose of an NCA iS to allow
for public comments on sipuleucel-T and the benefits and risks that have
been experienced in real-world patients treated with the drug. The NGA
is expected to last until mid-2011, and the results of this CMS review will
ultimately dictate Medicare's final position on sipuleucel-T coverage. 15
As of March 30, 2011, Medicare's NGA of sipuleucel-T had completed,
and the overall therapeutic and economic balance of its risks and benefits tipped the scales in its favor. 16 Sipuleucel-T's statistically significant
4.1-month increase in median survival rate, mild adverse effects, and acceptable but controversial CUA supported the FDA's intention of use in
patients and persuaded Medicare to reimburse payment for its indicated
use as private insurers have already done. The drug's specific target
treatment population of castration-resistant prostate cancer had a positive effect in Medicare's decision, especially since it is the only remaining
systemic treatment currently approved for use in these patients other
than chemotherapy. Pending a 30-day period allowing an opportunity
for public comment, Medicare will issue a memorandum stating this
final decision. While Medicare has not approved off-label use of this
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immunotherapy due to inadequate evidence demonstrating sipuleucel-T's
effectiveness in other treatment populations, it has decided to allow local
contractors to determine eligibility for other proposed uses, but it would be
willing to reconsider this decision if more evidence presents itself in the
future. Although at a high cost to taxpayers, Medicare's decision to cover
the use of sipuleucel-T offers the possibility of an extended life expectancy to affected Americans.
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